Natera (NASDAQ:NTRA) CEO Steven Leonard Chapman Sells 1,273 Shares of Company Stock

Natera, Inc. (NASDAQ:NTRA) CEO Steven Chapman sold 1,273 shares of the business’s stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $413.31, for a total transaction of $526,143.63. Following the transaction, the chief executive officer directly owned 96,926 shares of the company’s stock, valued at $40,060,485.06. The trade was a 1.30% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Steven Leonard Chapman also recently made the following trade(s):

• On Tuesday, September 1st, Steven Chapman sold 1,698 shares of Natera stock. The shares were sold at an average price of $320.99, for a total value of $545,041.02.
• On Monday, August 3rd, Steven Chapman sold 3,076 shares of Natera stock. The stock was sold at an average price of $266.39, for a total value of $819,415.64.
• On Tuesday, July 28th, Steven Chapman sold 3,580 shares of Natera stock. The shares were sold at an average price of $254.07, for a total value of $909,570.60.
• On Monday, July 27th, Steven Chapman sold 2,190 shares of Natera stock. The stock was sold at an average price of $260.49, for a total value of $570,473.10.

Natera Stock Up 3.7%

NASDAQ NTRA opened at $425.64 on Tuesday. The company has a 50-day moving average price of $335.75 and a 200-day moving average price of $263.06. Natera, Inc. has a 52 week low of $167.21 and a 52 week high of $427.47. The firm has a market capitalization of $61.35 billion, a P/E ratio of -312.97 and a beta of 1.50.

Natera (NASDAQ:NTRA) last announced its earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.49) by $0.02. The company had revenue of $752.75 million during the quarter, compared to analyst estimates of $661.24 million. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The firm’s quarterly revenue was up 37.7% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.74) earnings per share. As a group, equities research analysts anticipate that Natera, Inc. will post -1.02 EPS for the current year.

Hedge Funds Weigh In On Natera

Institutional investors have recently bought and sold shares of the stock. Trust Co. of Vermont bought a new position in shares of Natera during the 2nd quarter valued at about $26,000. Reflection Asset Management purchased a new stake in shares of Natera in the fourth quarter worth about $29,000. Elevation Wealth Partners LLC bought a new position in Natera during the second quarter valued at approximately $30,000. Palladiem LLC bought a new position in Natera during the fourth quarter valued at approximately $31,000. Finally, Continuum Advisory LLC bought a new stake in Natera in the 2nd quarter worth approximately $33,000. 99.90% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have recently commented on NTRA shares. Robert W. Baird set a $348.00 price objective on Natera in a research note on Friday, August 7th. Royal Bank Of Canada increased their target price on shares of Natera from $350.00 to $460.00 and gave the stock an “outperform” rating in a report on Friday, September 25th. BTIG Research raised their target price on shares of Natera from $290.00 to $320.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. Piper Sandler upped their price target on shares of Natera from $249.00 to $363.50 and gave the stock an “overweight” rating in a research report on Wednesday, August 12th. Finally, Canaccord Genuity Group set a $375.00 target price on shares of Natera in a research note on Friday, August 7th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $341.55.

About Natera

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to assess genetic and disease-related risks. The company uses technologies including cell-free DNA analysis and next-generation sequencing to support clinical decision-making in reproductive health, oncology and organ transplantation.

Its reproductive health offerings include Panorama, a noninvasive prenatal test that screens for certain chromosomal conditions, and Horizon, a carrier screening test that evaluates whether prospective parents carry genetic variants associated with inherited disorders.